Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease
Status:
Completed
Trial end date:
2014-11-06
Target enrollment:
Participant gender:
Summary
Alzheimer's disease is a devastating neurodegenerative disorder, for which there is currently
no effective treatment to slow or halt progression. Beta amyloid peptide accumulates in the
brains of those with Alzheimer's, and is thought to play a major role in triggering the
dementia. The investigators recently characterized a molecular pathway by which ß-amyloid
damages neurons, and showed that the protein termed Fyn kinase is crucial. Our data suggest
that blocking Fyn will have a significant therapeutic benefit for Alzheimer's. Astra Zeneca
has developed a blocker of Fyn and related kinases (AZD0530) for the treatment of cancer.
Chronic AZD0530 administration is well tolerated in humans, and the investigators propose to
test its potential as a novel Alzheimer's disease modifying therapy. This study will assess
the safety and tolerability of AZD0530 in patients with Alzheimer's disease.
Phase:
Phase 1
Details
Lead Sponsor:
Stephen M. Strittmatter
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)